Array And Oncothyreon Team Up On Oral HER2 Inhibitor
This article was originally published in The Pink Sheet Daily
Oncothyreon agreed to pay $10 million upfront for rights to Array’s oral HER2 inhibitor in development for breast cancer. Under the arrangement, Oncothyreon will fund and conduct proof-of-concept studies, but both companies will be responsible for Phase III development and potentially commercialization.
You may also be interested in...
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.